GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Establishment Labs Holdings Inc (NAS:ESTA) » Definitions » Debt-to-EBITDA

ESTA (Establishment Labs Holdings) Debt-to-EBITDA : -5.75 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Establishment Labs Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Establishment Labs Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.1 Mil. Establishment Labs Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $198.2 Mil. Establishment Labs Holdings's annualized EBITDA for the quarter that ended in Sep. 2024 was $-34.7 Mil. Establishment Labs Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -5.75.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Establishment Labs Holdings's Debt-to-EBITDA or its related term are showing as below:

ESTA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.34   Med: -2.11   Max: -1.07
Current: -4.34

During the past 8 years, the highest Debt-to-EBITDA Ratio of Establishment Labs Holdings was -1.07. The lowest was -4.34. And the median was -2.11.

ESTA's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs ESTA: -4.34

Establishment Labs Holdings Debt-to-EBITDA Historical Data

The historical data trend for Establishment Labs Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Establishment Labs Holdings Debt-to-EBITDA Chart

Establishment Labs Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -1.90 -2.11 -2.04 -3.16 -3.30

Establishment Labs Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.00 -2.78 -4.92 -4.95 -5.75

Competitive Comparison of Establishment Labs Holdings's Debt-to-EBITDA

For the Medical Devices subindustry, Establishment Labs Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Establishment Labs Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Establishment Labs Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Establishment Labs Holdings's Debt-to-EBITDA falls into.



Establishment Labs Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Establishment Labs Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.773 + 191.451) / -58.307
=-3.30

Establishment Labs Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.148 + 198.185) / -34.684
=-5.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Establishment Labs Holdings  (NAS:ESTA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Establishment Labs Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Establishment Labs Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Establishment Labs Holdings Business Description

Traded in Other Exchanges
Address
Coyol Free Zone, Building B15 and 25, Alajuela, CRI
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Executives
Chacon Quiros Juan Jose director, officer: Chief Executive Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Nicholas Sheridan Lewin director, 10 percent owner 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Raj Denhoy officer: Chief Financial Officer C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Dennis E Condon director 811 ALSTON RD, SANTA BARBARA CA 93108
Leslie Gillin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul D. Rodio officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Samuel Ross Mansbach other: GC & Chief Compliance Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Jw Asset Management, Llc 10 percent owner, other: See Footnote(1) 1051 N VENETIAN DRIVE, MIAMI BEACH FL 33139
Bryan Slotkin director C/O MOTIVA USA,.LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Ann Custin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Edward J Schutter director C/O FIRST HORIZON PHARMACEUTICAL CORP, 6195 SHILOH ROAD, ALPHARETTA GA 30005
Lisa Gersh director C/O HASBRO, INC., 1011 NEWPORT AVENUE, PAWTUCKET RI 02861
Mezerville Roberto De officer: Chief Technology Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Renee Gaeta officer: Chief Financial Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Pratip Dastidar officer: Head of Global Operations 150 PEABODY PLACE, MEMPHIS TN 38103